Subsequent Events	6 Months Ended
Dec. 31, 2025
Subsequent Events [Abstract]
Subsequent Events	15. Subsequent Events Effective February 12, 2026, our stockholders approved our 2026 Stock Omnibus Equity Compensation Plan (the 2026 Plan), which replaces the MEI Pharma, Inc. 2008 Omnibus Equity Compensation Plan, as amended and restated (the Prior Plan). Subject to certain adjustments, under the 2026 Plan, we are authorized to issue 2,000,000 shares of Common Stock, plus (i) the number of shares available for grant under the Prior Plan as of the effective date of the 2026 Plan and (ii) the number of shares underlying awards granted under the Prior Plan that, following the effective date, expire or are terminated, surrendered, cancelled or forfeited without issuance of shares. Grants may be made to our employees and the employees of our affiliates, our nonemployee directors, and the advisors who perform services for us and our subsidiaries. The 2026 Plan provides for the grant of stock options, stock appreciation rights, stock units, stock awards, and other stock-based awards. Except as provided below, the 2026 Plan is administered by our compensation committee, which will determine the individuals who will receive grants under the 2026 Plan, the type and size of such grant, and otherwise make all determinations under the 2026 Plan as it deems necessary. In the case of nonemployee directors, our Board will perform the functions of the compensation committee under the 2026 Plan. The 2026 Plan will terminate on February 11, 2036, unless terminated earlier by the Board or unless the Board, with stockholder approval, extends the term of the 2026 Plan.

Subsequent Events

6 Months Ended

Dec. 31, 2025

15. Subsequent Events

Effective February 12, 2026, our stockholders approved our 2026 Stock Omnibus Equity Compensation Plan (the 2026 Plan), which replaces the MEI Pharma, Inc. 2008 Omnibus Equity Compensation Plan, as amended and restated (the Prior Plan). Subject to certain adjustments, under the 2026 Plan, we are authorized to issue 2,000,000 shares of Common Stock, plus (i) the number of shares available for grant under the Prior Plan as of the effective date of the 2026 Plan and (ii) the number of shares underlying awards granted under the Prior Plan that, following the effective date, expire or are terminated, surrendered, cancelled or forfeited without issuance of shares. Grants may be made to our employees and the employees of our affiliates, our nonemployee directors, and the advisors who perform services for us and our subsidiaries. The 2026 Plan provides for the grant of stock options, stock appreciation rights, stock units, stock awards, and other stock-based awards. Except as provided below, the 2026 Plan is administered by our compensation committee, which will determine the individuals who will receive grants under the 2026 Plan, the type and size of such grant, and otherwise make all determinations under the 2026 Plan as it deems necessary. In the case of nonemployee directors, our Board will perform the functions of the compensation committee under the 2026 Plan. The 2026 Plan will terminate on February 11, 2036, unless terminated earlier by the Board or unless the Board, with stockholder approval, extends the term of the 2026 Plan.